Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CTSA | P10619 | 6/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | EEF2K | O00418 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841303 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16322089 | 0.89 | CYP3A4 (0.70) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16322092 | 0.89 | CYP3A4 (0.70) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL17857468 | 0.88 | CYP3A4 (0.60) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16320771 | 0.88 | CYP3A4 (0.72) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16320772 | 0.88 | CYP3A4 (0.72) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16320779 | 0.85 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16320781 | 0.85 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL17841291 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL17841290 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | TNNI3, NME4, TNNT2 | CYP3A4 2865/4885CYP2B6 1968/4885SMN1; SMN2 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.